European Pharmaceutical Contract Manufacturing Market Expected to Grow 6.1% Per Year to 2028 –


DUBLIN–(BUSINESS WIRE)–The “European Contract Manufacturing of Pharmaceuticals Market Forecast 2022-2028” report has been added to from offer.

European pharmaceutical contract manufacturing is expected to have a considerable CAGR of around 6.1% over the forecast period. Outsourcing pharmaceutical manufacturing products to outside vendors through a formal agreement is known as pharmaceutical contract manufacturing.

Contract manufacturing organizations serve the pharmaceutical industry and provide services related to drug manufacturing and development. Outsourcing with CDMO allows pharmaceutical industries to significantly expand their business and technical resources, and allows pharmaceutical companies to reduce drug development costs and save time for subsequent processes.

Additionally, the pharmaceutical contract manufacturing company provides a range of services to pharmaceutical companies, including drug development, manufacturing and commercial production, pre-formulation, FDA regulatory compliance documentation, among others. .

The growth of the pharmaceutical industry owing to the increasing demand for pharmaceuticals and the high expenditure in R&D activities are the major factors driving the growth of the European pharmaceutical contract manufacturing market. According to the European Federation and Association of Pharmaceutical Industries in 2018, the production of pharmaceutical products reached $315 billion and $442 billion was invested in R&D. Moreover, the growing demand for generic drugs and the presence of major players are further contributing to the growth of the market.

However, quality control issues and shift to Asia-Pacific countries such as India and China for pharmaceutical outsourcing are hampering the growth of the European pharmaceutical contract manufacturing market. Additionally, advancements in drug discovery and increasing R&D investments by contract manufacturers are expected to create a significant opportunity for the market in the near future.

Main topics covered:

1. Summary of the report

2. Overview and Market Overview

3. Competitive Landscape

4. Market drivers

5. Market segmentation

6. Regional analysis

7. Company Profiles

Companies cited

  • Aenova Group

  • Almac Group Ltd.

  • Aurena Laboratories AB

  • Baxter Healthcare Corp.

  • Beltapharm SpA

  • Boehringer Ingelheim International GmbH

  • Catalent Inc.

  • Cenexi SAS

  • CordenPharma International GmbH

  • Delorbis Pharmaceuticals Ltd.

For more information on this report, visit


Comments are closed.